Program
cadonilimab
Also written as “AK104”, “Cadonilimab” and “Cadonilimab (AK104)”.
Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Carcinoma, Renal Cell · Stomach Neoplasms, led by 4 companies.
Drug pageCadonilimab: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akesoits history only | 4219 open or running | phase 3since Jul 21, 2021 | Aug 20, 2017 | Nov 2026phase 3 · NCT06341335 |
| RemeGen | 11 open or running | phase 3since Jan 15, 2024 | Jan 15, 2024 | Dec 2026phase 3 · NCT06221748 |
| Shanghai Pharmaceuticalsits history only | 11 open or running | phase 2since Jul 6, 2023 | Jul 6, 2023 | Dec 31, 2026phase 2 · NCT05944224 |
| Summit Therapeuticsits history only | 11 open or running | phase 2since Sep 29, 2026 | Sep 29, 2026 | Apr 12, 2029phase 2 · NCT07877194 |
Also a collaborator on its studies: Chipscreen Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of RemeGen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named cadonilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AK104
- Jan 15, 2024First study: phase 3 study in Stomach NeoplasmsFirst studyNCT06221748 · 90 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsNCT06221748
TargetBeta
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
The one study RemeGen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06221748Stomach Neoplasms · China | 3 | Recruiting | Dec 2026 | 90 |
How it is read
Names in the registry
- “AK104”, 26 entries
- “Cadonilimab”, 3 entries
- “Cadonilimab (AK104)”, 3 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “AK104+anlotinib”, 3 entries
Codes read as this program: AK104.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 6 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Uterine Cervical Neoplasms, 4 studies
- Carcinoma, Renal Cell, 2 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.